| scholarly article | Q13442814 |
| P50 | author | Frank B Furnari | Q56528881 |
| Cristel V Camacho | Q62760543 | ||
| Kimmo Hatanpaa | Q91409013 | ||
| P2093 | author name string | Webster K Cavenee | |
| David A Boothman | |||
| Robert M Bachoo | |||
| Bipasha Mukherjee | |||
| Christopher Madden | |||
| Elizabeth Maher | |||
| Nozomi Tomimatsu | |||
| Sandeep Burma | |||
| Bruce Mickey | |||
| Brian McEllin | |||
| Shyam Sirasanagandala | |||
| Suraj Nannepaga | |||
| P2860 | cites work | Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. | Q44880688 |
| Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation | Q45106730 | ||
| A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis | Q46091026 | ||
| EGFRvIII-mediated radioresistance through a strong cytoprotective response | Q50335608 | ||
| PIKK-ing a new partner: a new role for PKB in the DNA damage response. | Q53479497 | ||
| Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. | Q53595531 | ||
| Amplification and differential expression of members of the erbB-gene family in human glioblastoma. | Q55482407 | ||
| Epidermal growth factor receptor and Ink4a/Arf | Q57277079 | ||
| Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis | Q73937525 | ||
| Integration of EGFR inhibitors with radiochemotherapy | Q79227019 | ||
| Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance | Q80410939 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway | Q24650927 | ||
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 | ||
| The EGF receptor family: spearheading a merger of signaling and therapeutics | Q28289369 | ||
| DNA repair pathways as targets for cancer therapy | Q29615572 | ||
| Malignant astrocytic glioma: genetics, biology, and paths to treatment | Q29618156 | ||
| The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. | Q33198320 | ||
| Second messenger systems in human gliomas | Q33301928 | ||
| Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide | Q33341259 | ||
| Use of kinase inhibitors to dissect signaling pathways. | Q33979180 | ||
| Role of non-homologous end joining (NHEJ) in maintaining genomic integrity | Q34544982 | ||
| The HER family and cancer: emerging molecular mechanisms and therapeutic targets | Q34558080 | ||
| Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis | Q34992049 | ||
| A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity | Q35660849 | ||
| Role of DNA-PK in the cellular response to DNA double-strand breaks | Q35848450 | ||
| p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. | Q36693887 | ||
| PTEN enters the nuclear age. | Q36705731 | ||
| Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis | Q37115208 | ||
| The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling | Q38349130 | ||
| Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced ce | Q38612684 | ||
| Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation | Q39504308 | ||
| Modulation of the DNA-damage response to HZE particles by shielding. | Q39955124 | ||
| Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. | Q39958695 | ||
| PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival | Q39987929 | ||
| Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma | Q40124686 | ||
| Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. | Q40259700 | ||
| DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells | Q40299419 | ||
| Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment | Q40310878 | ||
| Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase | Q40401323 | ||
| Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. | Q40464510 | ||
| Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). | Q40505815 | ||
| Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme | Q40512036 | ||
| Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin | Q40568043 | ||
| Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). | Q40612218 | ||
| Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. | Q40792458 | ||
| DNA-dependent protein kinase-independent activation of p53 in response to DNA damage | Q40950612 | ||
| Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. | Q41256548 | ||
| Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib | Q43742602 | ||
| Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells | Q44010963 | ||
| Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. | Q44605155 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 4252-4259 | |
| P577 | publication date | 2009-05-12 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma | |
| P478 | volume | 69 |
| Q38683823 | A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants |
| Q47109034 | A molecular view of the radioresistance of gliomas |
| Q33802003 | ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks |
| Q53692403 | ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. |
| Q34044691 | Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes |
| Q35966249 | Activated platelets rescue apoptotic cells via paracrine activation of EGFR and DNA-dependent protein kinase. |
| Q35112737 | Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo. |
| Q95363061 | Centromere-associated protein E expresses a novel mRNA isoform in acute lymphoblastic leukemia |
| Q35058799 | Challenges in EGFRvIII detection in head and neck squamous cell carcinoma |
| Q39354541 | Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma |
| Q33583028 | Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma |
| Q38066230 | Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma |
| Q26778614 | Cross talk of tyrosine kinases with the DNA damage signaling pathways |
| Q35229306 | Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells |
| Q38094808 | Current and future directions for Phase II trials in high-grade glioma |
| Q35608458 | DNA damage response and repair: insights into strategies for radiation sensitization of gliomas |
| Q37897385 | DNA double-strand break - induced pro-survival signaling |
| Q38106985 | DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy |
| Q34203095 | DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. |
| Q26740256 | DNA repair mechanisms and their clinical impact in glioblastoma |
| Q50995887 | DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair. |
| Q60305163 | Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo |
| Q37322983 | Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value |
| Q34286305 | Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. |
| Q92421826 | Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma |
| Q26768265 | Differential Superiority of Heavy Charged-Particle Irradiation to X-Rays: Studies on Biological Effectiveness and Side Effect Mechanisms in Multicellular Tumor and Normal Tissue Models |
| Q51062624 | Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer. |
| Q60044757 | Drug and disease signature integration identifies synergistic combinations in glioblastoma |
| Q36006229 | Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells |
| Q58562119 | EGFR confers radioresistance in human oropharyngeal carcinoma by activating endoplasmic reticulum stress signaling PERK-eIF2α-GRP94 and IRE1α-XBP1-GRP78 |
| Q24338426 | EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment |
| Q38199643 | EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. |
| Q38261455 | EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells. |
| Q89748217 | EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma |
| Q38912207 | EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. |
| Q38607113 | ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition |
| Q52676603 | Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells. |
| Q38928657 | Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87. |
| Q48210380 | Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas |
| Q34542656 | Emerging treatment strategies for glioblastoma multiforme |
| Q34999744 | Emodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptor/epidermal growth factor receptor variant III in glioma stem cells |
| Q38973740 | Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. |
| Q38101608 | Enhancing radiation therapy for patients with glioblastoma |
| Q34105339 | Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance |
| Q39472366 | Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation |
| Q39640913 | Epothilone B Confers Radiation Dose Enhancement in DAB2IP Gene Knock-Down Radioresistant Prostate Cancer Cells |
| Q64109379 | Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma |
| Q37256404 | Extracellular ATP protects endothelial cells against DNA damage |
| Q50130110 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. |
| Q90053127 | Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma |
| Q39772659 | Glycogen synthase kinase 3beta inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons |
| Q37902873 | Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers |
| Q37628728 | Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors |
| Q34241614 | High Expression of SOX2 and OCT4 Indicates Radiation Resistance and an Independent Negative Prognosis in Cervical Squamous Cell Carcinoma |
| Q35806672 | Identification of an AAA ATPase VPS4B-dependent pathway that modulates epidermal growth factor receptor abundance and signaling during hypoxia. |
| Q39202072 | Impact of carbon ion irradiation on epidermal growth factor receptor signaling and glioma cell migration in comparison to conventional photon irradiation |
| Q35558949 | Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation |
| Q34988108 | Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells |
| Q97530158 | Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer |
| Q37626600 | Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma |
| Q47136533 | Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab |
| Q36412815 | Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 |
| Q35556981 | Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells |
| Q34062038 | JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma |
| Q30588679 | Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling |
| Q34180263 | Loss of p15/Ink4b accompanies tumorigenesis triggered by complex DNA double-strand breaks. |
| Q39366909 | Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer |
| Q37130116 | MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma |
| Q55457100 | MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. |
| Q37666955 | MET signaling promotes DNA repair and radiation resistance in glioblastoma stem-like cells |
| Q39679745 | MRE11 and ATM AKTivate pro-survival signaling |
| Q90168903 | Mesenchymal stem cell therapy assisted by nanotechnology: a possible combinational treatment for brain tumor and central nerve regeneration |
| Q47996105 | MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. |
| Q38754926 | Musashi1 Impacts Radio-Resistance in Glioblastoma by Controlling DNA-Protein Kinase Catalytic Subunit. |
| Q37665446 | New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity |
| Q38728613 | Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway |
| Q46897628 | Oligosaccharide G19 inhibits U-87 MG human glioma cells growth in vitro and in vivo by targeting epidermal growth factor (EGF) and activating p53/p21 signaling |
| Q50053407 | Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells |
| Q37808385 | PI3Kinase signaling in glioblastoma |
| Q33958963 | PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. |
| Q39650727 | Pharmacologic Inactivation of Kinase Suppressor of Ras1 Sensitizes Epidermal Growth Factor Receptor and Oncogenic Ras-Dependent Tumors to Ionizing Radiation Treatment |
| Q42468364 | Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma |
| Q28252635 | Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer |
| Q64278894 | Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas |
| Q34349820 | RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients |
| Q38873993 | Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles |
| Q49451574 | Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer |
| Q100750414 | Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma |
| Q35200273 | Regulators of homologous recombination repair as novel targets for cancer treatment. |
| Q39687738 | Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas |
| Q38374667 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study |
| Q34758639 | Reverse engineering of modified genes by Bayesian network analysis defines molecular determinants critical to the development of glioblastoma |
| Q38047648 | Reversion of the ErbB malignant phenotype and the DNA damage response. |
| Q38183283 | Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness. |
| Q28274124 | Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment |
| Q92025312 | Roles and mechanisms of alternative splicing in cancer - implications for care |
| Q37856721 | Strategies to improve radiotherapy with targeted drugs |
| Q61136284 | Stromal PTEN determines mammary epithelial response to radiotherapy |
| Q27334035 | Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia |
| Q34848038 | Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity. |
| Q33908683 | TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway |
| Q38815297 | Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). |
| Q37960389 | Targeting DNA repair and the cell cycle in glioblastoma |
| Q37981764 | Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. |
| Q33598694 | Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy |
| Q38344592 | Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma |
| Q55313011 | Targeting Long Noncoding RNA HMMR-AS1 Suppresses and Radiosensitizes Glioblastoma. |
| Q42602597 | Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. |
| Q34138796 | Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization |
| Q51060657 | Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells. |
| Q35763894 | The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses |
| Q27015045 | The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered |
| Q38255481 | The future of glioblastoma therapy: synergism of standard of care and immunotherapy |
| Q39167423 | The role of radiation in treating glioblastoma: here to stay |
| Q52590668 | Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways. |
| Q33903166 | Wnt activation promotes neuronal differentiation of glioblastoma |
| Q39713171 | XPC silencing sensitizes glioma cells to arsenic trioxide via increased oxidative damage |
| Q37154455 | mRNA splicing variants: exploiting modularity to outwit cancer therapy |
Search more.